Related Experiment Video
Updated: Jun 25, 2026

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin
Published on: March 10, 2021
Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells
Aline Martayan1, Leonardo Sibilio, Elisa Tremante
1Laboratory of Immunology, Regina Elena Cancer Institute Centro della Ricerca Sperimentale, Rome, Italy.
Insights
Human Leukocyte Antigen (HLA) class I molecules can fold and function without beta(2)-microglobulin (beta(2)m) in a unique cell line, offering new avenues for tumor immunotherapy.
Area of Science:
- Immunology
- Molecular Biology
- Cell Biology
Background:
- Human Leukocyte Antigen (HLA) class I molecules are crucial for presenting viral and tumor antigens to T cells.
- Proper assembly of HLA class I molecules requires the beta(2)-microglobulin (beta(2)m) light chain.
- Cells lacking beta(2)m exhibit significant folding abnormalities in HLA class I molecules.
Purpose of the Study:
- To investigate the folding and function of HLA class I molecules in the absence of beta(2)m.
- To characterize the structural and functional properties of HLA class I heavy chains in beta(2)m-defective cells.
- To explore the potential of beta(2)m-defective cells for therapeutic applications, such as tumor immunotherapy.
Main Methods:
- Utilized eight conformational murine monoclonal antibodies (mAbs) and four human mAbs to map HLA class I epitopes.
- Employed radioimmunoprecipitation, in vitro assembly, pulse-chase, and flow cytometry techniques.
- Conducted peptide-pulse/ELISPOT experiments to assess antigen presentation.
Main Results:
- Endogenous and transfected HLA heavy chains are expressed on the cell surface of beta(2)m-defective Daudi cells as immature glycoforms.
- HLA-A2 heavy chains exhibit partial folding at critical interfaces and are receptive to exogenous peptides.
- HLA-A2 molecules can present exogenous viral and tumor antigens to cytotoxic T lymphocytes.
Conclusions:
- Demonstrated a stepwise, ligand-induced folding mechanism for HLA class I heavy chains in vitro and in vivo.
- Established Daudi cells as the first human cell line capable of folding and presenting antigens via HLA class I molecules without beta(2)m.
- Highlighted the potential implications of HLA class I plasticity for advancing tumor immunotherapy strategies.
Abstract:
To present virus and tumor Ags, HLA class I molecules undergo a complex multistep assembly involving discrete but transient folding intermediates. The most extensive folding abnormalities occur in cells lacking the class I L chain subunit, called beta(2)-microglobulin (beta(2)m). Herein, this issue was investigated taking advantage of eight conformational murine mAbs (including the prototypic W6/32 mAb) to mapped H chain epitopes of class I molecules, four human mAbs to class I alloantigens, as well as radioimmunoprecipitation, in vitro assembly, pulse-chase, flow cytometry, and peptide-pulse/ELISPOT experiments. We show that endogenous (HLA-A1, -A66, and -B58) as well as transfected (HLA-A2) heavy chains in beta(2)m-defective Burkitt lymphoma Daudi cells are capable of being expressed on the cell surface, although at low levels, and exclusively as immature glycoforms. In addition, HLA-A2 is: 1) partially folded at crucial interfaces with beta(2)m, peptide Ag, and CD8; 2) receptive to exogenous peptide; and 3) capable of presenting exogenous peptide epitopes (from virus and tumor Ags) to cytotoxic T lymphocytes (bulk populations as well as clones) educated in a beta(2)m-positive environment. These experiments demonstrate a precursor-product relationship between novel HLA class I folding intermediates, and define a stepwise mechanism whereby distinct interfaces of the class I H chain undergo successive, ligand-induced folding adjustments in vitro as well as in vivo. Due to this unprecedented class I plasticity, Daudi is the first human cell line in which folding and function of class I HLA molecules are observed in the absence of beta(2)m. These findings bear potential implications for tumor immunotherapy.
Related Concept Videos
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
Antigen Presenting Cells
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...

